Gladice Wallraven
Gradalis (United States)(US)
Publications by Year
Research Areas
Sarcoma Diagnosis and Treatment, Cancer Genomics and Diagnostics, CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers, Cancer Research and Treatments
Most-Cited Works
- → Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial(2020)112 cited
- → Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma(2016)94 cited
- → Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma(2015)53 cited
- → Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer(2021)35 cited
- → Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer(2021)23 cited
- → Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA(2023)21 cited
- → Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance(2020)21 cited
- → Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer(2015)20 cited
- → Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer(2022)18 cited
- → Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer(2021)17 cited